Table 2.
Comparison of benign tumours versus carcinomas. Vascularisation after administration of CM [0.5 ml Optison]
| Benign tumours (n=29) | Carcinomas (n=71) | |||
|---|---|---|---|---|
| Power Doppler | Power Doppler +CM | Power Doppler | Power Doppler + CM | |
| Early phase (1–5 min) | ||||
| Marginal vessels | 11/29 (38%) | 24/29 (83%) | 43/71 (60%) | 67/71 (94%) |
| Penetrating vessels | 4/29 (14%) | 12/29 (41%) | 28/71 (39%) | 65/71 (91%) (p<0.05) |
| Central vessels | 0/29 (0%) | 6/29 (20%) | 21/71 (29%) | 48/71 (68%) (p<0.05) |
| Late phase (5–20 min) | ||||
| Diffuse enhancement | 0/29 | 0/29 | 0/71 | 65/71 (91%) (p<0.01) |
Marginal vessels are seen in both groups in a high percentage. Most carcinomas show diffuse enhancement through the late phase (statistical evaluation with the Fisher’s exact test, significant differences p<0.05)